@HelioSader

Senior Director for Microbiology and Surveillance @ JMI Laboratories

 North Liberty, IA
jmilabs.com/
Joined April 2022
  • Tweets13
  • Following19
  • Followers16
10Media
.@HelioSader's most recent article out @BSACandJAC: Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) doi.org/10.1093/jac/dkac233
https://doi.org/10.1093/jac/dkac233

ALT https://doi.org/10.1093/jac/dkac233

1
It's been a busy few months. A few weeks ago on May 17 I presented "New BL/BLI Combos against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units" at @atscommunity tinyurl.com/2byfrwh3
1
Thank you!
Alex Lepak@a_lepak25 May 2022
Replying to @a_lepak @OncIDPharmd
@heliosader @mcastanheirajmi have a nice article of complexity ceftaz-avi resistance in PsA too!!!
From "Antimicrobial Susceptibility of Organisms Isolates from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)" @jmilabs #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/ECC…
Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

ALT Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

3
From "Bloodstream infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)" @jmilabs #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/ECC…
Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

ALT Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

1
From "Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021" @nabriva #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/21-…
Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021

ALT Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021

From "Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)" @nabriva #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/21_…
From Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)"

ALT From Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)"

From "Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021)" @pfizer #eccmid2022 See the full presentation here: jmilabs.com/data/posters/ECC…
From Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021)

ALT From Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021)

From "Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)" @abbvie #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/21-…
Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)

ALT Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)

1
From "Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New B-Lactamase Inhibitor Combinations" @abbvie #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/ECC…
Antimicrobial Susceptibility of Enterobacterales Causing Infections in ICU Patients: The Role of New B-Lactamase Inhibitor Combinations

ALT Antimicrobial Susceptibility of Enterobacterales Causing Infections in ICU Patients: The Role of New B-Lactamase Inhibitor Combinations

2
From "Comparative Activity of Newer B-lactam/B-lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICUs of US Medical Centres in 2021" @abbvie #ECCMID2022 See the full presentation here: jmilabs.com/data/posters/ECC…
Conclusions from Comparative Activity of Newer B-Lactam/B-Lactamase Inhibitor Combinations against P. aeruginosa from Patients in ICU of US Medical Centres in 2021

ALT Conclusions from Comparative Activity of Newer B-Lactam/B-Lactamase Inhibitor Combinations against P. aeruginosa from Patients in ICU of US Medical Centres in 2021

I'll tweet snippets from my #ECCMID2022 posters over the next few days. Research was supported by @abbvie, @jmilabs, @nabriva, and @pfizer.
1
Hello! I'll be in Lisbon for #ECCMID2022 with @jmilabs. Here's a list of my posters and presentations. Love to see you there.
1
Load more